Coya Therapeutics, Inc.
corporate_fare Company Profile
Coya Therapeutics, Inc. (NASDAQ:COYA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for COYA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for COYA spans 10-Q, 8-K, 424B5, 424B3.
Recent high-impact activity:
- Coya Posts Wider-Than-Expected Q3 Loss, Revenue Down 93%, Going-Concern Warning
- Coya 10-Q Flags Going Concern: $35.8M Cash, $86.4M Deficit, $10.6M Q3 Loss
- Coya Therapeutics Completes Full Enrollment of 120 Patients in Phase 2/3 ALSTARS Trial for COYA 302 in ALS
- Coya Therapeutics Q2 2026: $43.2M Cash, ALSTARS Enrollment on Track, Topline Data Expected Q1 2027
- Coya Therapeutics Q2 Cash Runway Past ALS Data, Fast Track Designation Secured
Financial Snapshot
Short Interest & Short Volume
11.89 days to coverFINRA reported short interest of 1,410,974 shares in COYA as of the October 30, 2026 settlement, a 12.4% increase from the prior period — about 11.9 days to cover at its recent average daily volume. On November 20, 2026, 39.6% of COYA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.